In vitro cytotoxic activities, DNA-, and BSA-binding studies of a new dinuclear copper(II) complex with N-[3-(dimethylamino)propyl]-N'-(2-carboxylatophenyl)-oxamide as ligand.
A new dinuclear copper(II) complex bridged by N-[3-(dimethylamino)propyl]-N'- (2-carbo-xylatophenyl)oxamide (H3 dmapob), and endcapped with 2,2'-diamino-4,4'-bithiazole (dabt), namely [Cu₂(dmapob)(dabt)(CH₃OH)(pic)]·(DMF)₀.₇₅ ·(CH₃OH)₀.₂₅ has been synthesized and characterized by elemental analysis, molar conductivity measurement, infrared and electronic spectra studies, and single-crystal X-ray diffraction. In the crystal structure, both copper(II) ions have square-pyramidal coordination geometries. The Cu···Cu separation through the oxamido bridge is 5.176(9) Å. A two-dimensional supramolecular framework is formed through hydrogen bonds and π-π stacking interactions. The reactivities toward herring sperm DNA and bovine serum albumin (BSA) show that the complex can interact with the DNA via intercalation mode and bind to the BSA responsible for quenching of tryptophan fluorescence by the static quenching mechanism. The in vitro anticancer activities suggest that the copper(II) complex is active against the selected tumor cell lines. The influence of different bridging ligands in dinuclear complexes on the DNA- and BSA-binding properties as well as anticancer activities is preliminarily discussed.
Marine Drug & Food Institute Ocean University of China, Qingdao, Shandong, 266003, People's Republic of China.
Jing
J
Jiao
Man
M
Jiang
Yan-Tuan
YT
Li
Zhi-Yong
ZY
Wu
Cui-Wei
CW
Yan
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D001665:Binding Sites; D002417:Cattle; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D056831:Coordination Complexes / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D003300:Copper / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D018360:Crystallography, X-Ray; D004247:DNA / Q000378:metabolism*; D055664:Electrochemical Techniques; D006801:Humans; D006860:Hydrogen Bonding / Q000187:drug effects; D008024:Ligands; D008958:Models, Molecular; D010072:Oxamic Acid / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D012235:Rhodamines / Q000378:metabolism; D012710:Serum Albumin, Bovine / Q000378:metabolism*; D013050:Spectrometry, Fluorescence; D013056:Spectrophotometry, Ultraviolet; D014783:Viscosity / Q000187:drug effects
D000970:Antineoplastic Agents; D056831:Coordination Complexes; D008024:Ligands; D012235:Rhodamines; C022027:lissamine rhodamine B; D012710:Serum Albumin, Bovine; D003300:Copper; D004247:DNA; D010072:Oxamic Acid; C008728:oxamide
Crystal Structure; DNA and BSA Binding; Dicopper(II) Complex; In Vitro Cytotoxic Activities; µ-Oxamido-Bridge